3T Biosciences

T-Therapeutics

The company develops T cell receptor therapeutics and bispecific engagers for patients with cancer and autoimmune diseases.

Neogene Therapeutics

This biotechnology company develops engineered T cell receptor therapies targeting neoantigens in solid cancers for patients with oncology needs.

PanCancerT

This biotech company develops T-cell receptor therapies for patients with solid tumours, focusing on targets like triple-negative breast cancer and melanoma.

ImmunoScape

This biotechnology company develops T-cell receptor immunotherapies and immune profiling platforms for pharmaceutical firms and academic researchers to treat solid tumours.

Ypsilon Therapeutics

The company develops T-cell receptor mimic antibodies and bispecific T-cell engagers to treat patients with solid tumours, such as triple-negative breast and lung cancer.

CTRL Therapeutics

This company develops cell therapies for solid tumours and microfluidic platforms to identify rare tumour-reactive lymphocytes for cancer patients.

ArsenalBio

The company develops programmable T cell therapies for patients with solid tumours and autoimmune diseases.

Swarm Oncology

This biotechnology company develops personalised T cell therapies for patients with advanced solid cancers to achieve long-term remission.